Global Mesothelioma Deaths Remain High Despite Poor Data

An estimated 38,400 people around the world will die this year from mesothelioma cancer, according to a report recently published in Occupational &Environmental Medicine. The estimation by the international peer-reviewed journal included 230 countries. Data used for the study came from the World Health Organization’s (WHO) Mortality Database and extrapolated information based on gender- and age-specific death rates. “The global burden of mesothelioma is real,” Dr. Ken Takahashi, director of Asbestos Diseases Research Institute, University of Sydney Gate 3, Australia, told Asbestos.com. “It is visible in the developed world but hidden and unrealized in the still-developing world.” Takahashi is the senior author of a team of scientists and doctors from Japan, Australia, United States, United Kingdom, Thailand and Singapore who used 1994-2014 data to complete the report. Mesothelioma, a relatively rare and aggressive cancer caused almost exclusively by exposure to asbestos, has no definitive cure. Reliable Mesothelioma Data Is Rare Researchers determined only 59 countries kept reliable data on mesothelioma deaths, while 45 countries had poor quality data, and 126 countries reported no data on mesothelioma. “There were a lot of surprises, in a sense. Countries where there had been a lot of asbestos exposure, but very few recorded deaths from mesothelioma,” Dr. Christina Fitzmaurice, University of Washington Medicine, hematologist, onc...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Asbestos Diseases Research Institute asbestos-related lung cancer Australia mesothelioma Bangladesh Dr. Christina Fitzmaurice Dr. Ken Takahashi Global Burden of Disease Mesothelioma death rate mesothelioma latency period mesothelioma uni Source Type: news

Related Links:

Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSION: In this contest, MacroH2A.1 overexpression supports its function as an epigenetic stabilizer that helps to establish and maintain differentiated states. PMID: 32077824 [PubMed - as supplied by publisher]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at Asbestos.com. “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is highly aggressive neoplasm, with a median survival of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The U.S. Food and Drug Administration moved closer on Tuesday to formulating standardized testing of talc-based products for the presence of toxic asbestos fibers. Experts from eight different federal agencies explained earlier recommendations at a day-long hearing. The session also featured input from 25 members of the public, which included industry representatives, consumer advocates and testing experts. “Standards are needed,” said Dr. Paul Howard, FDA Office of Regulatory Science, during his presentation. “They just don’t exist at this time.” Dr. Linda Katz, director of the FDA Office of ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Background: Pemetrexed is an antifolate cytostatic drug that targets multiple enzymes involved in folate biosynthesis and is indicated for treatment of non–small-cell lung cancer and malignant pleural mesothelioma. As evidence for an exposure–response/toxicity relationship is accumulating, dose individualization using therapeutic drug monitoring may be a feasible strategy to optimize treatment. The purpose of this study was to develop a simple, sensitive, high-performance liquid chromatography method with UV detection for quantification of pemetrexed levels in human plasma. Method: The method involves a si...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Short Communication Source Type: research
Publication date: Available online 10 January 2020Source: Pathology - Research and PracticeAuthor(s): Masanori Matsuda, Hironori Ninomiya, Ryo Wakejima, Kentaro Inamura, Sakae Okumura, Mingyon Mun, Masanobu Kitagawa, Yuichi IshikawaAbstractCalretinin, a mesothelioma marker, is sometimes expressed in lung cancer, which may complicate the differential diagnosis of mesothelioma. Here, the clinicopathological and immunohistochemical characteristics of calretinin-positive lung cancer were examined to reduce confusion with malignant mesothelioma. Calretinin expression in 307 consecutive cases of lung cancer was evaluated immunoh...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
A patient diagnosed with pleural and peritoneal mesothelioma today can survive well beyond expectations, provided personalized treatment can be found at a specialty center. Research from the Columbia University Medical Center in New York City has shown that despite the poor prognosis typically accompanies this rare diagnosis, patients still can thrive. “This is an understudied, and poorly understood, group of patients that often is just written off,” surgical oncologist Dr. Michael Kluger at Columbia told The Mesothelioma Center at Asbestos.com. “But we’ve shown a meaningful survival.” Kluger,...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Australia Health | Bangladesh Health | Cancer | Cancer & Oncology | Databases & Libraries | Environmental Health | Hematology | Japan Health | Lung Cancer | Mesothelioma | Occupational Health | Russia Health | Singapore Health | Study | Thailand Health | UK Health | University of Washington | USA Health